Merck Still Sees ‘Compelling’ Outlook for Terns Leukemia Drug

Why It Matters

The TERN‑701 asset gives Merck a promising chronic myeloid leukemia therapy to diversify revenue as Keytruda’s patent cliff approaches, illustrating disciplined, data‑driven M&A.

Key Takeaways

• Merck paid $6.7 billion for Terns, $53 per share.
• Updated TERN‑701 data shows >50% major molecular response at 24 weeks.
• TERN‑701 outperforms Novartis’ Scemblix 25% MMR rate.
• Deal saved Merck roughly $1 billion versus earlier higher bids.
• Adds a pipeline asset as Keytruda nears patent expiry.

Pulse Analysis

The acquisition of Terns Pharmaceuticals marks a strategic win for Merck, whose due‑diligence team uncovered compelling efficacy signals in TERN‑701, a chronic myeloid leukemia (CML) candidate. The drug’s major molecular response rate—projected above 50% after 24 weeks—significantly exceeds the 25% benchmark set by Novartis’ Scemblix, positioning TERN‑701 as a potential new standard of care in a market hungry for more durable treatments. By securing the asset at $53 a share, Merck not only captured a high‑value pipeline addition but also avoided a near‑$1 billion premium that earlier bidders were prepared to pay.

Merck’s broader portfolio faces a looming revenue challenge as Keytruda, its flagship immunotherapy, approaches the end of its patent life. Keytruda currently drives more than half of Merck’s pharmaceutical sales, and the company has publicly acknowledged that replicating its success is unlikely. TERN‑701 therefore serves as a critical hedge, complementing other late‑stage candidates such as the cholesterol‑lowering enlicitide, the blood‑pressure drug Winrevair, and the oncology product Welireg. By diversifying across therapeutic areas, Merck aims to sustain growth momentum and reassure investors that the post‑Keytruda era will be underpinned by a robust, multi‑product pipeline.

The Terns deal also signals a broader shift in biotech M&A, where rigorous data validation can dramatically reshape valuation. Merck’s disciplined approach—walking away from a $61‑per‑share offer with contingent value rights and returning with a lower, data‑backed bid—demonstrates how scientific insight can translate into tangible financial savings. As regulators scrutinize CML endpoints, the company’s confidence in the trial’s patient‑level data may accelerate FDA discussions, potentially shortening time to market. For the industry, the transaction underscores the premium placed on late‑stage assets that combine strong efficacy with clear regulatory pathways, setting a benchmark for future acquisition strategies.